Influence of seretide and budesonide on immune function and pulmonary function in patients with moderate and severe bronchial asthma

Objective To investigate the influence of seretide and budesonide on immune function and pulmonary function in patients with moderate to severe bronchial asthma. Methods 120 patients with moderate to severe bronchial asthma were chosen as experimental objects, and were divided into a control group and a research group. The control group were treated with budesonide, and the research group with seretide. After the treatment, the clinical effects, immune function, pulmonary function, and adverse reactions were compared between two group. Results The total effective rate of the research group was higher than that of the control group (95.00% vs. 96.67%), with a statistical difference (P 0.05). After the treatment, the FEV1 [(1.82±0.39)L vs. (1.53±0.51)L], FVC[(2.76±0.37)L vs. (2.51±0.23)L], and PEF [(277.87±56.57)L/mm vs. (251.59±54.30)L/mm] were higher in the research group than in the control group (P 0.05). Conclusions Seretide is superior to Budesonide aerosol inhalation in the treatment of moderate and severe bronchial asthma, and has better clinical efficacy and safety. Key words: Bronchial asthma; Budesonide; Seretide; Immune function; Pulmonary function